ACRV:NASDAQ, Acrivon Therapeutics, Inc.

Why ACRV stock fell on November 20

Acrivon Therapeutics, Inc. fell 17.9% on Friday, November 20, 2026, on 1,294,096 shares, 5.0 times its average daily volume. No headline about ACRV came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

ACRV stock overview

Acrivon Therapeutics, Inc. (ACRV:NASDAQ) closed at $1.15 on November 20, 2026, down 17.86% on the day. The stock trades 67.7% below its 52-week high of $3.56 and 18.4% above its 52-week low of $0.971. Over the past year, it lost 51.3%. Acrivon Therapeutics, Inc. is part of the Health Care sector.

Key figures

Price
$1.15
Day change
-17.86%
Volume
1,294,096
Average volume
261,106
Market cap
49M+
52-week range
$0.971 – $3.56
50-day average
$1.78
200-day average
$1.74

Price action over the past year

In 252 trading sessions since November 20, 2025, ACRV closed higher on 111 days (44%). Its best day was January 6, 2026 (+31.44%) and its worst was January 8, 2026 (-34.58%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

ACRV news

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Similar stocks

Find more stocks like ACRV with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.